Oncogenes Are Here to Stay
It has been speculated for many years that some cancers might represent the consequence of one or several discrete genetic changes in the tumor cells. Studies of xeroderma pigmentosum (XP) cells revealed genetic lesions that predispose cells to be more susceptible to the carcinogenic effects of ultraviolet radiation (UV). Although these genes render it more likely that XP cells exposed to UV will be converted to the transformed state, their genetic defect does not directly convert cells toward the tumorigenic phenotype. In contrast to these susceptibility genes, cellular oncogenes (c-one) represent a class of genes whose protein products can convert normal cells directly to the transformed state [1] [2] [3] [4] . Recent studies of the oncogenes have had a major impact on our understanding of carcinogenesis, although the precise role of c-one in individual tumors often remains maddeningly obscure.
Under normal conditions, c-one probably carry out functions that are critical to cellular growth and differentiation [5, 6] . The normal, appropriately regulated versions of these genes are often called proto-oncogenes (proto-one). A proto-one can be "activated" to function abnormally and contribute to the tumorigenic phenotype by either of two mechanisms: by its expression at inappropriately high levels, leading to high levels of its protein product, or by mutation ofthe sequences encoding the protein product of the gene. Using these criteria, activated c-one (also called cellular transforming genes) have been found in a variety of spontaneous human cancers [1] [2] [3] [4] , as well as in many chemical [7, 8] and virus-induced tumors of animals [9] , including cutaneous tumors [7, 10, 11] .
Detection of Oncogenes
As often happens, technical innovations have led to the identification and characterization of these genes. These technical advances have enabled investigators to obtain clear answers to certain questions that previously would have required experiments that were prohibitively complex, might have yielded ambiguous results, or could not even have been carried out. We owe our current knowledge of cellular transforming genes to multiple advances in molecular biology: the discovery of restriction endonucleases, the development of molecular cloning technology, and the establishment of relatively efficient techniques for the stable transfer of genes into mammalian cells [12] .
The initial studies of c-one were carried out by tumor virologists. It had been recognized for many years that certain proteins encoded by the strongly transforming retroviruses (such as the src gene product of Rous sarcoma virus) have the capacity to directly induce tumorigenic transformation of cultured cells and endow these viruses with their high oncogenic potential [13] . It became clear during the late 1970s that each viral oncogene (v-onc) had actually been derived from a cellular gene that had been stably acquired by the retrovirus. Approximately 25 different v-one have now been identified. The availability of these purified v-one genes enabled investigators to identify, isolate, and characterize the normal cellular genes (proto-one) from which the v-one had been derived. It should be emphasized that these studies quickly established that each proto-one represented an ordinary cellular gene that had nothing to do with the virus which had enabled the cellular gene to be identified. Further investigation also demonstrated that each proto-one was conserved in evolution, as is true of many other cellular genes. This means that human cells (and cells from 495 other species) contain proto-one that are homologous to the vane of each transforming virus.
Given this presence in all animal cells of cellular genes that are homologous to viral transforming genes, it was logical to ask whether cellular DNA obtained from tumors that had not been induced by viruses might contain cellular genes that could be tumorigenic for tissue culture cells. This phenomenon was demonstrated when DNA from human and animal tumor cell lines were able to induce tumorigenic transformation of mouse NIH 3T3 tissue culture cells [1] [2] [3] [4] 13] . These results were highly significant: in a given tumor, the same gene was consistently responsible for inducing cellular transformation, while similar preparations of DNA from normal cells were uniformly negative in the cell transformation assay.
Many activated c-one genes have now been isolated by the cell transformation assay described above. In this assay, morphologic transformation by these genes represents a genetically dominant trait. Some cellular transforming genes that are unrelated to known v-one genes have been detected by this powerful gene transfer technique [14] . However, most of the cone isolated thus far by this procedure have proved to be one of the ras genes, which are a family of closely related cellular genes that were first identified from the v-one of Harvey and Kirsten sarcoma viruses [15] . Point mutations in sequences encoding specific amino acids of the transforming ras protein products enable them to transform NIH 3T3 and other established rodent tissue culture lines.
Other activated c-one have been identified biochemically by molecular hybridization techniques. Burkitt lymphoma was the first human tumor shown consistently to express abnormally elevated levels of a cellular gene that was a v-onc homolog. In this tumor, the cellular gene was c-mye, which is the cellular homolog of a viral oncogene (v-mye) that has been found in several transforming viruses [16] . c-mye has been activated in this class of B-cell tumor by the mechanism of chromosomal translocation. It had been previously recognized that virtually all Burkitt lymphoma cells possess a chromosomal translocation which invariably involved a particular region of chromosome 8. This region was translocated onto specific regions of any one of three other chromosomes: 2, 14, and 22. Following the assignment of c-mye to chromosome 8, and the three immunoglobulin chain genes (lgK, lgJ.L, and lgi\) to chromosomes 2, 14, and 22, respectively, it was quickly established t hat the inappropriate expression of c-myc was the consequence of chromosomal translocation involving c-myc and any one of the three immunoglobulin genes. The expression of the translocated c-mye gene has been activated by sequences located within the immunoglobulin genes, which contain t issue-specific enhancers (sequences that specifically interact with the milieu of B cells to increase the level of RNA transcription of genes in their vicinity).
Molecular hybridization techniques have also identified several c-one that are related to, but distinct from, the authentic cellular homologs of v-one genes. For example, amplification (increased gene copy number) and elevated expression of a cellular gene called N-mye has been found in some human neuroblastomas [ 17) . This gene was detected by virtue of its homology with mye.
Two other approaches have been utilized to identify cellular genes that may turn out to be oncogenes. One method is to screen tumors induced by retroviruses that do not carry t heir own v-one gene; the purpose of this search is to see whether the viral DNA has integrated preferentially in a particular chromosomal site in several different tumors induced by the virus. This approach is based on the observation that when avian leukosis virus (a retrovirus that does not contain an oncogene) induces bursal lymphomas in chickens, it usually does so by activating the chicken c-myc gene. In these tumors, the viral DNA, which contains an enhancer element, has integrated adjacent to c-myc, leading to c-myc activation [9] . Using a similar approach, analysis of other tumors induced by retroviruses has identified virally activated cellular genes that are not related to any known v-onc but which may also function as oncogenes [18] .
The second strategy has been to analyze the genes involved in the breakpoints of chromosomal translocations found to be characteristic for certain tumor types (reviewed in [19] ) . The potential validity of this approach is based on the examples of c-myc with Burkitt lymphoma noted earlier and c-abl (the cellular homolog of the v-abl oncogene of Abelson leukemia virus), which is found at the breakpoint of the Philadelphia chromosome t ranslocation associated with most cases of chronic myelogenous leukemia.
Role in Oncogenesis
Activated c-one have been found in many different histologic types of tumors. The activation of c-one usually represents a . somatic change that is confined to the tumor cells. In most instances, oncogene activation does not appear to be the consequence of a lesion in the proto-one of the germ cells of the affected individual. However, there are preliminary data suggesting that some proto-one associated with certain malignancies may not have been entirely normal [20] . As noted earlier, the precise role of cellular transforming genes in human tumors has not yet been elucidated. In experimental tumors associated with c-one activation, a very high proportion of the tumors contain the same activated gene [7] [8] [9] . By contrast, activated oncogenes have usually been detected in only a minority of spontaneously arising tumors of a given histologic type. This observation suggests that activation of a particular oncogene is not absolutely necessary to develop what seems to be a particular type of tumor. Even in those tumors in which activated oncogenes have beeen found, it is not yet clear whether these changes play a major role in the early events of the cancer process. A wealth of data suggests, however, that oncogene activation can enchance the malignant potential of a given cell.
The data from experimental tumorigenesis and clinical observation strongly suggests that the progression from a normal to a malignant cell does not occur as a single-step process (reviewed in [1] ) . Human cells appear to be particularly difficult to transform in vitro to the fully tumorigenic phenotype. Results obtained with activated c-one in primary rodent cells have been consistent with the multistep hypothesis of tumorigenesis. Although an activated e-ras gene can induce full transformation of established tissue culture cell lines, this same gene may not by itself induce full transformation of primary rodent cells. However, t he primary rodent cells can be transformed to the tumorigenic phenotype by introducing a second oncogene such as myc in addition to the activated e-ras [1] .
Many tumors have been described that contain more than one activated oncogene (reviewed in [1] ) . It seems reasonable to conclude that the oncogenic activity of two oncogenes will be greater than that of either one by itself. It also appears likely that particular combinations of oncogenes may have greater malignant potential than others. Some investigators believe that certain oncogenes (such as myc) function principally as immortalization genes (that prolong the lifespan of the cell), while other oncogenes (such as ras) function principally as genes that transform cells morphologically.
Some oncogenes may be tissue specific in their tumorigenic activity. Instructive results have been obtained with c-fos, Vol. 85 
at levels similar to those in placenta leads to the induction of osteogenic sarcomas in mice. These results emphasize the notion that inappropriate expression, rather than merely the level of expression, may have a determining influence on tumorigenicity. One laboratory has found consistent activation of other genes correlates closely with a given type of tumor (14] . On the other hand, activated ras and myc genes have been detected in many different tumor types, suggesting that these genes may contribute to the tumorigenic phenotype in widely divergent tumors.
Function of Oncogene Encoded Proteins
It is very likely that c-one serve important functions in normal growth and development, given their high degree of conservation among widely divergent species and their capacity to alter the proliferative capacity of cells. In addition to being present in all vertebrates, many c-one have also been found in invertebrate animal species, such as Drosophila. Even more striking has been the identification of ras genes in yeast (21] .
Since these genes act on cells through their protein products, one genes should probably be grouped according to the functions of these proteins. An extremely important area for future research will be to elucidate the mechanisms by which these proteins act and to determine the cellular pathways in which they fall. Results obtained thus far suggest that there are several classes of these proteins [22] .
The ras genes of Harvey and Kirsten sarcoma viruses were the first example of two different one genes recognized as being related to each other. The ras gene family is comprised of at least three different biologically active genes in mammals [ 15] . The three genes encode proteins that are closely related to each other, are found at the plasma membrane, possess GTPase activity that is significantly lower in activated ras genes, and share homology with so-called G proteins (regulatory proteins of the adenylate cyclase system). Microinjection of ras-specific antibody into NIH 3T3 cells prevents their undergoing DNA synthesis, suggesting that ras protein is essential for the growth of these cells and perhaps other cell types [6] .
Experiments in yeast suggest that the yeast ras also subserve a function that is essential to their life cycle. In addition, mammalian ras genes can substitute functionally for yeast ras, and activated versions of yeast ras genes can morphologically transform mouse NIH 3T3 cells [21] . These results suggest that these genes probably function similarly in mammalian cells and in yeast. Since it is in principle much easier to develop cell mutants in yeast than in higher eukaryotic cells, it seems likely that elucidation of the cellular pathway for ras protein function in yeast will have direct implications for the function of the mammalian ras proteins.
Other one genes have been found to be part of another large gene family, which has been designated the src gene family [22] because the v-src gene of Rous sarcoma virus is the prototype for the proteins they encode. Most of their proteins possess a tyrosine kinase activity that correlates closely with their transforming activity.
Some proto-one related to v-onc have turned out to be genes that nonvirologists have studied as cell-encoded proteins. The v-erb 8 gene, which is a member of the src gene family, represents a truncated version of the epidermal growth factor (EGF) receptor [23] . This gene has been found in the avian erythroblastosis virus; as its name implies, this virus induces erythroblastosis in chickens. Elevated expression of this gene has been reported in a variety of epithelial tumors, including some cutaneous squamous cell carcinomas [11] . The sis gene found in another retrovirus represents a somewhat altered version of the gene that encodes platelet-derived growth factor (PDGF), which is believed to play a significant role in wound healing [24] .
The proteins encoded by myc, fos, and several other oncogenes are found in t he nucleus, where some appear to be DNA binding proteins. Marked changes in t he expression of fo s have been noted shortly after stimulation of quiescent tissue cult ure cells (5] .
Future Prospects
It seems probable that some of t he most interesting chapters in research on these genes are yet to be written. The analysis of o ncoge nes has foc used principally on their role in malignant tumors. The cont inued study of these genes and their protein products in malignancies will almost certainly contribute significant new knowledge to the field of oncogenesis. Further exploration of c-one may also lead to new insights in cell biology, molecular evolution, and the pathogenesis of nonmalignant disease, such as those conditions associated with abnormalities of cell proliferation or differentiation. For example, psoriasis or Darier's disease represents a disorder whose pathogenesis might involve inappropriate (but reversible) proto-one expression.
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